Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.76 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | PPOX | P50336 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504562 | 0.86 | DTYMK (0.81) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL26775 | 0.86 | DTYMK (1.00) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL29353295 | 0.86 | DTYMK (1.00) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL143541 | 0.86 | DTYMK (1.00) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL29388000 | 0.85 | DTYMK (0.97) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL2470206 | 0.85 | DTYMK (0.78) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL8577281 | 0.85 | DTYMK (0.97) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL4820050 | 0.83 | DTYMK (0.76) | DTYMKCASP6TSHRMEN1KMT2A | |
| SCHEMBL19292717 | 0.81 | SIRT6 (0.52) | DTYMKMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL13715527 | 0.81 | DTYMK (0.82) | DTYMKCASP6TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | claimed |
| EP-1797192-A1 | MODIFIED PROTEINS | Novo Nordisk Health Care AG (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| WO-2006035057-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-04-06 | — | — | WO | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| CN-1126436-A | Vitamin B12 mediated oral delivery systems for GCSF and EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| EP-3621989-B1 | METHOD OF CONTROLLING THE FORMATION OF PINK COLOR DURING ANTIBODY MANUFACTURING | BRISTOL MYERS SQUIBB CO (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230103511-A1 | METHOD OF CONTROLLING THE PINK COLOR GENERATED DURING ANTIBODY MANUFACTURING | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3621989-A1 | METHOD OF CONTROLLING THE FORMATION OF PINK COLOR DURING ANTIBODY MANUFACTURING | Bristol-Myers Squibb Company (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-110831964-A | Method of controlling pink color formation during antibody manufacture | 百时美施贵宝公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018208743-A9 | METHOD OF CONTROLLING THE FORMATION OF PINK COLOR DURING ANTIBODY MANUFACTURING | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-05 | — | — | WO | disclosed |
| WO-2018208743-A1 | METHOD OF CONTROLLING THE FORMATION OF PINK COLOR DURING ANTIBODY MANUFACTURING | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-15 | — | — | WO | disclosed |
| US-5041658-A | Indicator generates a variety of hues depending on the analyte concentration | MILES INC. (US) | 1991-08-20 | — | — | US | disclosed |
| US-5026897-A | Chemically mask cholinesterase enzymes; antispasmotic agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4975367-A | Catalytic test composition intended to produce a range of colors | MILES INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4973734-A | ANTIDIOTE FOR ORGANOPPHOSPHATE POISONING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1990-11-27 | — | — | US | disclosed |
| US-4898813-A | Catalytic test composition intended to produce a range of colors | MILES INC. | 1990-02-06 | — | — | US | disclosed |
| EP-0240849-A2 | Controlled hue test device | MILES INC. (US) | 1987-10-14 | — | — | EP | disclosed |
| EP-0239926-A2 | Rainbow test device | MILES INC. (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | DTYMK 266/4885CASP6 4095/4885TSHR 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.